STOCK PURCHASE AGREEMENT By and Between GENZYME CORPORATION AND ALNYLAM PHARMACEUTICALS, INC. Dated as of January 11, 2014Stock Purchase Agreement • May 9th, 2014 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of January 11, 2014, by and between Genzyme Corporation (the “Investor”), a Massachusetts corporation, with its principal place of business at 500 Kendall Street, Cambridge, MA 02142, and Alnylam Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, with its principal place of business at 300 Third Street, Cambridge, MA 02142.
STOCK PURCHASE AGREEMENT by and among ALNYLAM PHARMACEUTICALS, INC., SIRNA THERAPEUTICS, INC., MERCK SHARP & DOHME CORP., and solely for purposes of Sections 3.19, 5.2, 5.6, 9.2(b)(ii), 9.2(d) and ARTICLE XI herein, MERCK & CO., INC., Dated: January...Stock Purchase Agreement • May 9th, 2014 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
STOCK PURCHASE AGREEMENT, dated as of January 10, 2014, by and among Alnylam Pharmaceuticals, Inc. a Delaware corporation (“Buyer”), Sirna Therapeutics, Inc., a Delaware corporation (the “Company”), Merck Sharp & Dohme Corp., a New Jersey corporation (“Seller”), and solely for purposes of Sections 3.19, 5.2, 5.6, 9.2(b)(ii), 9.2(d) and Article XI herein, Merck & Co., Inc., a New Jersey corporation (“Merck”).
MASTER COLLABORATION AGREEMENT by and between ALNYLAM PHARMACEUTICALS, INC. and GENZYME CORPORATIONMaster Collaboration Agreement • May 9th, 2014 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS MASTER COLLABORATION AGREEMENT (this “Master Agreement”), entered into as of January 11, 2014 (the “Execution Date”), is entered into by and between Alnylam Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (“Alnylam”), and, Genzyme Corporation, a corporation organized and existing under the laws of the Commonwealth of Massachusetts (“Genzyme”).
INVESTOR AGREEMENT BY AND BETWEEN GENZYME CORPORATION AND ALNYLAM PHARMACEUTICALS, INC. DATED AS OF FEBRUARY 27, 2014Investor Agreement • May 9th, 2014 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS INVESTOR AGREEMENT (this “Agreement”) is made as of February 27, 2014, by and among Genzyme Corporation (“Investor”), a Massachusetts corporation with its principal place of business at 500 Kendall Street, Cambridge, MA 02142, and Alnylam Pharmaceuticals, Inc. (the “Company”), a Delaware corporation with its principal place of business at 300 Third Street, Cambridge, MA 02142.
